Hypomethylating agents can promote the expression of tumor testis antigens on both AML and MDS cells and induce CD8+ T cells to recognize silenced tumor-associated antigens (7, 8), ultimately exerting antitumor effects in myeloid neoplasms. Here, CD8A is linked to acute myeloid leukemia.